Madison, WINCT07494045Now EnrollingIRB Ready

CKD Stage 3 Clinical Trial in Madison, WI

Access cutting-edge ckd stage 3 treatment through this phase 2 clinical trial at a research site in Madison. Study-provided care at no cost to qualified participants.

Sponsored by OPKO Health, Inc.

Quick Self-Assessment

See if you qualify for this Madison location

Preparing your pre-screening questions…

Expert Care in Madison

Access ckd stage 3 specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related ckd stage 3 treatment provided free

Apply for This Madison Location

Check if you qualify for this ckd stage 3 clinical trial in Madison, WI

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Madison

    Convenient for WI residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Madison site if eligible
  4. 4Begin participation

About This CKD Stage 3 Study in Madison

The goal of this clinical trial is to evaluate safety, tolerability, and how CTAP101 Capsules work to treat Pediatric Participants with Secondary Hyperparathyroidism, Stage 3 or 4 Chronic Kidney Disease and Vitamin D Insufficiency. The main questions it aims to answer are: 1. To assess the pharmacokinetics (PK) and Pharmacodynamics (PD) of CTAP101 Capsules 2. To investigate the safety and tolerability of CTAP101 Capsules Participants will take a daily dosage of CTAP101 Capsules at bedtime for 8 weeks.

Sponsor: OPKO Health, Inc.

Who Can Participate

Inclusion Criteria

Each participant must meet the following criteria to be enrolled in Cohort 1 of this study:
Be 8 to \<18 years of age with a body weight of ≥40 kg.
Be diagnosed with stage 3 or 4 CKD at least six months prior to the screening visit (Visit 1) and have an eGFR of ≥15 to \<60 mL/min/1.73m2 at screening.
Be without any disease state or physical condition that might impair evaluation of safety or which, in the investigator's opinion, would interfere with study participation.
Exhibit during the initial or, if necessary, a screening visit after washout:
Plasma iPTH \>85 pg/mL;
Serum Ca \<9.8 mg/dL;
Serum P ≤5.5 mg/dL; and
Serum 25D \<30 ng/mL.
If taking calcitriol or other 1α-hydroxylated vitamin D therapy, be willing to forgo treatment with these agents for the duration of the study and complete a 2-week washout period prior to commencing treatment in the study.
If receiving ≤2,000 IU/day or 50,000 IU/month (1,250 mcg) vitamin D supplementation (ergocalciferol or cholecalciferol) therapy, must agree to remain on a stable dose during the study.
If taking \>2,000 IU/day of vitamin D supplementation, must discontinue or decrease the dose to ≤2,000 IU/day, maintain that dose for the duration of the study and complete a 2-week washout period prior to commencing treatment in the study.
If taking \>1000 mg/day of elemental Ca through Ca-based phosphate binder or antacid therapy, must discontinue or decrease the dose to ≤ 1000 mg/day, maintain that dose for the duration of the study, and complete a 2-week washout period prior to commencing treatment in the study.
If taking any bone metabolism therapy that could interfere with study endpoints, must discontinue use of such agent(s) for the duration of the study.
Willing and able to comply with study procedures and instructions and commit to all study visits for the duration of the study.
Willing and able to safely swallow the CTAP101 capsules whole.
Female participants of childbearing potential must be neither pregnant nor lactating and must have a negative urine pregnancy test at the first screening visit.
All female participants of childbearing potential and male participants with female partners of childbearing potential must agree to use effective contraception (eg, implants, injectables, combined oral contraceptives, intrauterine device, sexual abstinence, vasectomy or vasectomized partner) for the duration of the study.
Each participant or their legal representative must be able to read, understand and sign the ICF.

Exclusion Criteria

Participants who meet any of the following criteria will be excluded from the study:
Kidney transplant within the 26 weeks preceding screening or kidney transplant rejection within the 26 weeks preceding screening.
No history of parathyroidectomy or planned parathyroidectomy.
History (prior three months) of serum Ca ≥9.8 mg/dL.
Use of calcimimetic or calcifediol therapy within three months prior to consent.
Use of bisphosphonate or denosumab therapy within six months prior to consent.
Known or suspected hypersensitivity to any of the constituents in CTAP101 Capsules.
Known previous or concomitant serious illness or medical condition, such as malignancy, human immunodeficiency virus, significant gastrointestinal or hepatic disease or cardiovascular event or hepatitis, or abnormal ECG or physical condition that in the opinion of the investigator may worsen and/or interfere with participation in the study.
History of neurological/psychiatric disorder, including psychotic disorder, or any reason which, in the opinion of the investigator makes adherence to a treatment or FU schedule unlikely.
Currently participating in, or has participated in, an interventional/investigational study within 30 days prior to study screening that in the opinion of the investigator and/or sponsor would interfere with the safety, assessments, and results of this study.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Madison?

Yes, this clinical trial (NCT07494045) has an active research site in Madison, WI that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

CKD Stage 3 Treatment Options in Madison, WI

If you're searching for ckd stage 3 treatment options in Madison, WI, this clinical trial (NCT07494045) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Madison research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced ckd stage 3 specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all ckd stage 3 clinical trials near you to find additional studies recruiting in your area.

More Chronic Kidney Disease Trials in Madison, WI

See all chronic kidney disease clinical trials recruiting in Madison — not just this study.

Browse Chronic Kidney Disease Trials in Madison →

Browse More Trials by Condition

Chronic Kidney Disease TrialsAll Conditions →

Ready to Join in Madison?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Madison, WI